Nonparametric Regression Discontinuity Designs with Survival Outcomes

• URL: http://arxiv.org/abs/2604.03502v1
• Date: Fri, 03 Apr 2026 22:54:43 GMT
• Title: Nonparametric Regression Discontinuity Designs with Survival Outcomes
• Abstract summary: Quasi-experimental evaluations are central for generating real-world causal evidence and complementing insights from randomized trials.<n>The regression discontinuity design (RDD) is a quasi-experimental design that can be used to estimate the causal effect of treatments that are assigned based on a running variable crossing a threshold.<n>Standard RD estimators rely on complete outcome data, an assumption often violated in time-to-event analyses where censoring arises from loss to follow-up.<n>We propose a nonparametric approach that leverages doubly robust censoring corrections and can be paired with existing RD estimators.
• Score: 36.398652091809986
• License: http://arxiv.org/licenses/nonexclusive-distrib/1.0/
• Abstract: Quasi-experimental evaluations are central for generating real-world causal evidence and complementing insights from randomized trials. The regression discontinuity design (RDD) is a quasi-experimental design that can be used to estimate the causal effect of treatments that are assigned based on a running variable crossing a threshold. Such threshold-based rules are ubiquitous in healthcare, where predictive and prognostic biomarkers frequently guide treatment decisions. However, standard RD estimators rely on complete outcome data, an assumption often violated in time-to-event analyses where censoring arises from loss to follow-up. To address this issue, we propose a nonparametric approach that leverages doubly robust censoring corrections and can be paired with existing RD estimators. Our approach can handle multiple survival endpoints, long follow-up times, and covariate-dependent variation in survival and censoring. We discuss the relevance of our approach across multiple areas of applications and demonstrate its usefulness through simulations and the prostate component of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial where our new approach offers several advantages, including higher efficiency and robustness to misspecification. We have also developed an open-source software package, $\texttt{rdsurvival}$, for the $\texttt{R}$ language.

Related papers

• Orthogonal machine learning for conditional odds and risk ratios [0.0]
  We review existing methods and propose novel ones, focusing on the odds ratio (OR) and the risk ratio (RR)<n>We derive orthogonal risk functions for the OR and RR and show that the associated pseudo-outcomes satisfy second-order conditional-mean remainder properties analogous to the ATE case.<n>We also evaluate estimators for the conditional ATE, OR, and RR in a comprehensive nonparametric Monte Carlo simulation study to compare them with common alternatives under hundreds of different data-generating distributions.
  arXiv  Detail & Related papers  (2026-04-12T02:14:58Z)
• Overlap-weighted orthogonal meta-learner for treatment effect estimation over time [90.46786193198744]
  We introduce a novel overlap-weighted meta-learner for estimating heterogeneous treatment effects (HTEs)<n>Our WO-learner has the favorable property of Neyman-orthogonality, meaning that it is robust against misspecification in the nuisance functions.<n>We show that our WO-learner is fully model-agnostic and can be applied to any machine learning model.
  arXiv  Detail & Related papers  (2025-10-22T14:47:57Z)
• Flexible Nonparametric Inference for Causal Effects under the Front-Door Model [2.6900047294457683]
  We develop novel one-step and targeted minimum loss-based estimators for both the average treatment effect and the average treatment effect on the treated under front-door assumptions.<n>Our estimators are built on multiple parameterizations of the observed data distribution, including approaches that avoid mediator density entirely.<n>We show how these constraints can be leveraged to improve the efficiency of causal effect estimators.
  arXiv  Detail & Related papers  (2023-12-15T22:04:53Z)
• Doubly Robust Proximal Causal Learning for Continuous Treatments [56.05592840537398]
  We propose a kernel-based doubly robust causal learning estimator for continuous treatments. We show that its oracle form is a consistent approximation of the influence function. We then provide a comprehensive convergence analysis in terms of the mean square error.
  arXiv  Detail & Related papers  (2023-09-22T12:18:53Z)
• Discrete-time Competing-Risks Regression with or without Penalization [0.18416014644193068]
  We propose a new estimation procedure for discrete-time survival analysis with competing events.<n>A Python package, PyDTS, is available for applying the proposed method with additional features.
  arXiv  Detail & Related papers  (2023-03-02T11:57:10Z)
• Improved Policy Evaluation for Randomized Trials of Algorithmic Resource Allocation [54.72195809248172]
  We present a new estimator leveraging our proposed novel concept, that involves retrospective reshuffling of participants across experimental arms at the end of an RCT. We prove theoretically that such an estimator is more accurate than common estimators based on sample means.
  arXiv  Detail & Related papers  (2023-02-06T05:17:22Z)
• Robust and Agnostic Learning of Conditional Distributional Treatment Effects [44.31792000298105]
  We provide a new robust and model-agnostic methodology for learning the conditional DTE (CDTE) for a class of problems.<n>Our method is model-agnostic in that it can provide the best projection of CDTE onto the regression model class.<n>We investigate the behavior of our proposal in simulations, as well as in a case study of 401(k) eligibility effects on wealth.
  arXiv  Detail & Related papers  (2022-05-23T17:40:31Z)
• Assessment of Treatment Effect Estimators for Heavy-Tailed Data [70.72363097550483]
  A central obstacle in the objective assessment of treatment effect (TE) estimators in randomized control trials (RCTs) is the lack of ground truth (or validation set) to test their performance. We provide a novel cross-validation-like methodology to address this challenge. We evaluate our methodology across 709 RCTs implemented in the Amazon supply chain.
  arXiv  Detail & Related papers  (2021-12-14T17:53:01Z)
• Bayesian Uncertainty Estimation of Learned Variational MRI Reconstruction [63.202627467245584]
  We introduce a Bayesian variational framework to quantify the model-immanent (epistemic) uncertainty. We demonstrate that our approach yields competitive results for undersampled MRI reconstruction.
  arXiv  Detail & Related papers  (2021-02-12T18:08:14Z)
• Estimating heterogeneous survival treatment effect in observational data using machine learning [9.951103976634407]
  Methods for estimating heterogeneous treatment effect in observational data have largely focused on continuous or binary outcomes. Using flexible machine learning methods in the counterfactual framework is a promising approach to address challenges due to complex individual characteristics.
  arXiv  Detail & Related papers  (2020-08-17T01:02:14Z)
• Survival Analysis Using a 5-Step Stratified Testing and Amalgamation Routine in Randomized Clinical Trials [0.0]
  Increased patient heterogeneity can weaken the ability of common statistical approaches to detect treatment differences. A list of baseline covariates that have the potential to be prognostic for survival under either treatment is pre-specified. A conditional inference tree algorithm is used to segment the heterogeneous trial population into subpopulations of prognostically homogeneous patients. The impressive power-boosting performance of our proposed 5-step stratified testing and amalgamation routine (5-STAR) is illustrated.
  arXiv  Detail & Related papers  (2020-04-28T15:44:41Z)
• Bayesian Nonparametric Cost-Effectiveness Analyses: Causal Estimation and Adaptive Subgroup Discovery [0.0]
  We develop a nonparametric Bayesian model for joint cost-survival distributions in the presence of censoring. We use our model to assess the cost-efficacy of endometrial chemotherapy versus radiation adjuvant therapy for treating cancer in the SEER-Medicare database.
  arXiv  Detail & Related papers  (2020-02-11T21:51:58Z)

This list is automatically generated from the titles and abstracts of the papers in this site.

This site does not guarantee the quality of this site (including all information) and is not responsible for any consequences.